Over the past decade, the Centers for Disease Control and Prevention have seen a 57% rise in the reported new cases of Lyme disease and the best estimates suggest that approximately 300,000 individuals are diagnosed annually. This growing health concern is exacerbated by challenges in a timely and accurate diagnosis, as well as effective treatments that can eliminate protracted symptoms or prevent disease all together.
In an effort to address these challenges, the Institute for Next Generation Healthcare at Mount Sinai launched an ambitious program called LymeMIND, which plans to collect all existing molecular and clinical data into a unified model that can be used to better understand and treat Lyme disease.
This project is made possible by a generous gift from the Steven and Alexandra Cohen foundation.
This collaborative initiative is focused on creating a powerful community resource for continuous learning and discovery, with the ultimate goals to identify novel biomarkers to diagnosis and stratify patients, determine drug-repurposing options, and make connections to comorbidity and wellness.
2016 Lyme in the Era of Precision Medicine Conference
In October 2016, the Lyme Disease in the Era of Precision Medicine conference was held at Mount Sinai hosted by INGH bringing together leading scientists, physicians, and patient advocate groups, as well as patients and the general public to discuss the current challenges and propose paths forward for understanding this challenging disease. Panelists emphasized that scientists and physicians are often vexed as well by the prognosis for individuals. Stressing that an understanding of the molecular and cellular details of the immune response is essential because the immune system mediates both the clearance of Borellia infection—providing protection—and the post-treatment response—determining whether the consequences of infection become pathogenic. The top research priority going forward is the advancement of precision medicine methodologies aiming to identify the cause of post-treatment of lyme disease syndrome (PTLDS) for each individual to guide proper treatment course.
Click here for more information about our research in Lyme Disease.